低或无能量甜味剂和体重控制:剖析一个"小"的效果
1Consultant in Psychology of Food Intake, Paris, France.
概括
低能量或无能量甜味剂 (LNES) 可以通过取代糖的卡路里来帮助体重控制,从而提供适度的体重减轻. 它们的有效性与糖的取代成正比,可以支持饮食的坚持.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
- 肥胖问题研究研究
背景情况:
- 非营养甜味剂 (NNS) 是一个多世纪前开发出来的,目的是减少从糖类中摄入的卡路里,帮助减肥.
- 尽管NNS使用广泛,但全球肥胖率已达到流行病水平,造成了一个悖论.
- 本文探讨了NNS在体重管理中的作用,在肥胖率上升的背景下.
研究的目的:
- 为了解决NNS使用和增加肥胖率之间的明显悖论.
- 评估低能或无能甜味剂 (LNES) 对体重管理的影响.
- 分析LNES对人体体重的影响机制和程度.
主要方法:
- 基于能量平衡原则的分析.
- 对数十年来关于LNES和体重的研究进行了回顾.
- 评估LNES对饮料能量密度和消费者行为的影响.
主要成果:
- LNES通过一种营养机制影响体重,直接与从糖中取代的能量有关.
- LNES可以显著降低饮料的能量密度,对含糖饮料的消费者影响最大.
- 与手术或药物等其他干预措施相比,与LNES相关的平均体重减轻是适度的 (1-2公斤).
结论:
- LNES提供了诸如增加对甜食的腹感,改善饮食坚持以及支持减肥维护等好处.
- LNES的有效性与糖能位移的程度成正比.
- 虽然LNES提供了适度的体重减轻,但它们在当前肥胖环境中的整体意义是个人的观点问题.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Regulation of Food Intake
155
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
155
Overview of Carbohydrate Metabolism
573
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
573
Sugars as Energy Storage Molecules
8.2K
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
8.2K
Hypoglycemia and Glucagon
142
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
142


